Categories: New Launches

BD launches Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME) in conjunction with Joint Commission International (JCI) in India

New Delhi, April 15, 2019: BD (Becton, Dickinson and Company), a leading global medical technology company, has launched a new patient safety program for hospitals, called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME). Aimedat addressing the two critical challenges in a hospital setting – infection prevention and medication safety – PRIME is developed by Joint Commission International for Patient Safety, with sponsorship by BD.

Speaking about JCI’s initiation of PRIME with BD, Dr. Marwa J. Zohdy, Vice President, Global Consulting Services, Joint Commission Resources/Joint Commission International(JCI) said,“The preparation and administration of medication is critical to safe, high-quality patient care around the world.  At JCI, we recognize a fundamental need on this topic, and the unique PRIME program addresses that need.  Leading experts from JCI with the support of BD have created a practical curriculum that will bring critical skills to life.”

A unique programmatic approach towards patient safety will be implemented over a six-monthduration, composed of goal-setting, constant progress review, tele-consultations with experts and scientific updates through webinars. Hospitals will be certified upon successful completion of the program.

Emphasizing on launching PRIME in India, Pavan Mocherla, Managing Director, BD-India & South Asia said, “Increasingly, healthcare facilities across India are working to upgrade quality standards to achieve a future of better patient outcomes, increased patient safety and cost efficiency in healthcare systems. In this pursuit of quality and safety, BD is pleased to work on enabling the hospitals achieve standardized and compliant care and improve patient outcomes through PRIME – a Gold Standard benchmarked safety program with JCI. Through this hallmark program for hospitals, BD will be able to help enhance patient and clinical outcomes by eliminating complications and improving safety for patients and providers leading to accessing better care.”

So far, the hospitals that have signed up for the program in India are:

  1. Kolkata – Belle Vue Clinic, Fortis Hospital Anandapur
  2. Mumbai – Breach Candy, KokilabenDhirubhai Ambani Hospital & Medical Research Institute
  3. Trivandrum – Kerala Institute of Medical Sciences
  4. Manipal – Kasturba Hospital
  5. Mohali – Fortis Hospital
  6. Delhi/NCR – Max Healthcare, Saket and Medanta The Medicity-Gurgaon

PRIME has been launched across South Korea, Japan, Malaysia, Thailand, Indonesia, Philippines, Vietnam and India.

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

1 day ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

1 day ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

2 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

2 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

3 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

3 days ago